0.1108

3.45% 0.0037

After Hours: .11 -0.0008 -0.72%

Cns Pharmaceuticals Inc (CNSP)

Overview News Price History Financials Discussions Forecast Stock Split

Cns Pharmaceuticals Inc stock is traded at $0.1108, with a volume of 3.30M. It is up +3.45% in the last 24 hours and down -7.28% over the past month. CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Previous Close:

$0.1071

Open:

$0.1045

24h Volume:

3.30M

Relative Volume:

0.24

Market Cap:

$4.54M

Revenue:

Net Income/Loss:

$-18.61M

P/E Ratio:

-0.011

EPS:

-10.05

Net Cash Flow:

$-13.91M

1W Performance:

-19.54%

1M Performance:

-7.28%

6M Performance:

-99.00%

1Y Performance:

-99.89%

1-Day Range:

$0.1045

$0.1158

1-Week Range:

$0.10

$0.1381

52-Week Range:

$0.0955

$137.50

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Name

Cns Pharmaceuticals Inc

Sector

Healthcare (1182)

Industry

Biotechnology (680)

Phone

1-800-946-9185

Address

2100 WEST LOOP SOUTH, HOUSTON

Employee

Twitter

Next Earnings Date

2024-11-13

Latest SEC Filings

CNSP's Discussions on Twitter

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Stock (CNSP) Latest News

Nov 04, 2024

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire

Nov 04, 2024

Nov 03, 2024

CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World

Nov 03, 2024

Nov 01, 2024

CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com

Nov 01, 2024

CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024

CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com UK

Nov 01, 2024

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - AccessWire

Nov 01, 2024

Oct 25, 2024

Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content

Oct 25, 2024

Oct 23, 2024

CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia

Oct 23, 2024

CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com

Oct 23, 2024

CNS Pharmaceuticals secures $3 million in registered direct offering By Investing.com - Investing.com UK

Oct 23, 2024

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - AccessWire

Oct 23, 2024

CNS Pharmaceuticals faces NASDAQ delisting over price rule - Investing.com

Oct 23, 2024

Oct 14, 2024

Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.12, Up by 0.77 - The Dwinnex

Oct 14, 2024

Can you still get a good price for Cns Pharmaceuticals Inc (CNSP) Shares at this point? - US Post News

Oct 14, 2024

Oct 11, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates In Virtual Investor KOL Connect Segment - Barchart

Oct 11, 2024